Published on
October 10, 2022

B.More Psilocybin for AUD Program Principal Investigator, Dr. Michael Bogenschutz, to Present at Horizons New York Psychedelic Research Forum

Greenwich, Connecticut, October 10, 2022 – B. More Inc., a 501(c)(3) non-profit, clinical-stage biopharmaceutical company focused on the development of psychedelic medicines for substance abuse disorders, today announced that its Lead Site Principal Investigator, Dr. Michael Bogenschutz, Director of the NYU Langone Center for Psychedelic Medicine, will present at Horizons New York psychedelic research forum on Friday, October 14 at 11:30am Eastern Time. During his session, Psilocybin-assisted therapy for alcohol-use disorder, Dr. Bogenschutz will discuss the results of his Phase 2a trial of psilocybin for the treatment of alcohol use disorder, the largest psychedelic trial published in a peer-reviewed publication.

For further details or to register, to attend please visit:

Discounted tickets to attend in-person may be purchased using the code: BMORE-HNY-15

About B.More

Founded in 2017 by Carey and Claudia Turnbull, B.More is a 501(c)(3) non-profit, clinical-stage biopharmaceutical company with a mission to develop better treatment options for those struggling with alcohol use disorder and other substance use disorders. Named after Claudia Turnbull’s brother, Brett Moore, who died of a drug overdose 50 years ago, B.More is focused on the development and commercialization of psychedelic medicines that offer the potential to dramatically improve the lives of those for whom current treatment options have not proved effective. Based on a long history of partnership with researchers at the NYU School of Medicine, B.More is advancing clinical research to help these individuals and their loved ones live a better tomorrow.

For more information, please visit

Media inquiries:

Contact: Christopher Koddermann

Tel.: +41 (79) 434 25 78